Alexion Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It is the rare disease division of AstraZeneca.[1]
History
Alexion began collaborating with Moderna in January 2014, entering an agreement for ten product options based on Moderna's mRNA platform.[2][3] Alexion continued this work with Elpidera, a Moderna spinoff company launched in May 2015.[4]
COVID-19
The company had been running clinical trials on ULTOMIRIS (ravulizumab-cwvz) in hospitalized COVID-19 patients until they were paused in January 2021 due to lack of efficacy.[5]
Alexion became the rare disease division of AstraZeneca after being acquired by the company in 2021.[1:1]
Activities
Alexion awarded a $200,000 Rare Belonging grant to Ronald McDonald House Charities in 2020.[6]
External links
Kemp, A. (2021, July 21). Acquisition of Alexion completed. AstraZeneca. http://archive.today/2021.12.19-065821/https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html ↩︎ ↩︎
Elpidera. Moderna Therapeutics. Retrieved October 12, 2016, from http://archive.today/2016.10.12-231723/http://www.modernatx.com/our-business-model/ventures/elpidera ↩︎
Reidy, C. (2014, January 13). Alexion, Moderna announce agreement to develop messenger RNA therapeutics. Boston Globe Media Partners. https://web.archive.org/web/20230605072835/https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics/ ↩︎
Moderna Launches Third Venture Company Elpidera for Rare Diseases. (2015, May 12). Moderna Therapeutics. https://web.archive.org/web/20161012234942/http://www.modernatx.com/news-events/press-releases/moderna-launches-third-venture-company-elpidera-rare-diseases ↩︎
Goulart, M. (2021, January 13). Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19. Alexion Pharmaceuticals, Inc. http://archive.today/2022.01.12-213352/https://ir.alexion.com/news-releases/news-release-details/alexion-provides-update-phase-3-study-ultomirisr-ravulizumab ↩︎
Corporate Sponsors of RMHC. Ronald McDonald House Charities. Retrieved January 17, 2022, from http://archive.today/2022.01.13-065229/https://www.rmhc.org/about-us/our-partners ↩︎
